Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Rectal Neoplasms 3Pancreatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma 1

Interventions

Imatinib Mesylate 8Specimen Handling 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2temsirolimus 1rubitecan 1romidepsin 1oblimersen 1motexafin lutetium 1guadecitabine 1alvocidib 1Sorafenib 1Sirolimus 1Semaxinib 1Rogaratinib 1Nivolumab 1Leucovorin 1Irinotecan 1Immunoglobulin G 1HhAntag691 1Floxuridine 1Erlotinib Hydrochloride 1Doxorubicin 1Disulfides 1Dasatinib 1Cetuximab 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gastrointestinal Stromal Tumors × Dasatinib × Clear all
NCT01643278 2017-01-10

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡